Alex Kesin's Pharmacopoeia
Ruminations about biotech and drug development - one overly earnest blog post at a time. Click to read Alex Kesin's Pharmacopoeia, a Substack publication with thousands of subscribers.
- Posts
- 39 from 27 Apr 2021 to 18 Sep 2026
- Posting
- monthly (11 in the last year)
- Kind
- personal blog
- Feed
- https://www.alexkesin.com/feed
2026 9
- Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise
- China has caught up in biotech. How screwed are we?
- Side Effects May Include Artificially Inflated EPS
- Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time
- Pharma Is Hollywood, Roughly
- They Put a TB Vaccine Where?!
- Anti-Amyloids and Antichrist
- Episode #1: Amylin Pharmaceuticals
- A Better Proxy Than the Rat and Dog
2025 17
- Would Walter White Still Cook Meth in 2025?
- The three-thousand-year journey of colchicine
- Fun with FGF21
- How Amgen Lost The PCSK9 Patent War
- The Cowboy Of Generic Drugs
- The Day Novartis Chose Discovery
- July in Israel
- The Hollow Men of Hims
- Against "Against Life Extension"
- Biotech Life in the Software City
- Still Here, Still Jewish
- Mr. Secretary, Reclassify the Statin
- Charles River Is In Trouble
- China’s leap in pharma: slow and fast trends behind its rise
- 6 ways the new FDA can turbocharge drug development
- Narrow Leverage: How Small Strengths Create Big Power
- Prescription strength: musings about the past/present/future of sarcopenia therapeutics